Discounted Cash Flow (DCF) Analysis Levered

Cytek Biosciences, Inc. (CTKB)

$13.16

-0.31 (-2.30%)
All numbers are in Millions, Currency in USD
Stock DCF: -29.36 | 13.16 | overvalue

Free Cash Flow

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 57.8892.84127.95190.78284.46424.15632.43942.98
Revenue (%)
Operating Cash Flow -13.7515.16-4.75-7.08-10.56-15.75-23.48-35.01
Operating Cash Flow (%)
Capital Expenditure -0.97-1.55-2.14-3.19-4.76-7.10-10.58-15.78
Capital Expenditure (%)
Free Cash Flow -14.7213.61-6.89-10.28-15.32-22.84-34.06-50.79

Weighted Average Cost Of Capital

Share price $ 13.16
Beta 0.000
Diluted Shares Outstanding 81.54
Cost of Debt
Tax Rate 25.74
After-tax Cost of Debt 3.71%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.640
Total Debt -
Total Equity 1,073.10
Total Capital 1,073.10
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 57.8892.84127.95190.78284.46424.15632.43942.98
Operating Cash Flow -13.7515.16-4.75-7.08-10.56-15.75-23.48-35.01
Capital Expenditure -0.97-1.55-2.14-3.19-4.76-7.10-10.58-15.78
Free Cash Flow -14.7213.61-6.89-10.28-15.32-22.84-34.06-50.79
WACC
PV LFCF -10.65-15.32-22.04-31.71-45.62
SUM PV LFCF -116.70

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.64
Free cash flow (t + 1) -51.80
Terminal Value -3,158.79
Present Value of Terminal Value -2,641.70

Intrinsic Value

Enterprise Value -2,758.39
Net Debt -364.62
Equity Value -2,393.78
Shares Outstanding 81.54
Equity Value Per Share -29.36